Business
Takeda Presents Orexin Data from Landmark Oveporexton (TAK-861) Phase 3 Program in Narcolepsy Type 1 at World Sleep 2025
SINGAPORE & OSAKA, Japan & CAMBRIDGE, Mass., September 08, 2025--Takeda (TSE:4502/NYSE:TAK) will present data from two global Phase 3 double-blind, placebo-controlled studies of oveporexton (TAK-861)1, a potential first-in-class investigational oral orexin receptor 2 (OX2R)-selective agonist in narcolepsy type 1 (NT1), during multiple oral presentations at the World Sleep 2025 Congress in Singapore beginning at 3:15 p.m. SGT today.
About this update from Takeda Pharmaceutical Co. Ltd.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":266,"url":"https://media.zenfs.com/en/business-wire.com/e84cfdfa5960d57943419c6e7c9e22ed"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Uw.ezEaCY.MEztN_oIuSkQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTUzMjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/e84cfdfa5960d57943419c6e7c9e22ed","width":480,"height":266}},"lazy":false},{"type":"text","content":"– Takeda is the Leader in Orexin Science and is on Track to Submit Global Regulatory Applications Starting in Fiscal Year 2025","length":126,"tagName":"p","attribs":{}},{"type":"text","content":"– Four Orexin Oral Presentations from Phase 3 Pivotal Studies Highlight Statistically Significant and Clinically Meaningful Improvement in Narcolepsy Type 1 Symptoms Demonstrating the Potential for a New Era of Care","length":215,"tagName":"p","attribs":{}},{"type":"text","content":"– Oveporexton was Generally Well-Tolerated with Safety Profile Consistent with Previous Clinical Studies","length":104,"tagName":"p","attribs":{}},{"type":"text","content":"SINGAPORE & OSAKA, Japan & CAMBRIDGE, Mass., September 08, 2025--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) will present data from two global Phase 3 double-blind, placebo-controlled studies of oveporexton (TAK-861)1, a potential first-in-class investigational oral orexin receptor 2 (OX2R)-selective agonist in narcolepsy type 1 (NT1), during multiple oral presentations at the World Sleep 2025 Congress in Singapore beginning at 3:15 p.m. SGT today.","length":460,"tagName":"p"},{"type":"text","content":"Both the FirstLight (TAK-861-3001) and RadiantLight (TAK-861-3002) studies met all primary and secondary endpoints demonstrating statistically significant improvement across a broad range of NT1 symptoms compared to placebo with p-values of <0.001 across all doses (twice-daily 1mg/twice-daily 2mg) at week 12. Oveporexton was generally well-tolerated with a safety profile consistent across clinical studies to date. No serious treatment-related adverse events were reported. The most common adverse events were insomnia, urinary urgency and frequency.","length":556,"tagName":"p"},{"type":"text","content":"NT1 is a chronic, rare neurological disease caused by the loss of orexin neurons in ...